HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection.

AbstractBACKGROUND:
Controlled human malaria infection (CHMI) studies are a vital tool to accelerate vaccine and drug development. As CHMI trials are performed in a controlled environment, they allow unprecedented, detailed evaluation of parasite growth dynamics (PGD) and immunological responses. However, CHMI studies have not been routinely performed in malaria-endemic countries or used to investigate mechanisms of naturally-acquired immunity (NAI) to Plasmodium falciparum.
METHODS:
We conducted an open-label, randomized CHMI pilot-study using aseptic, cryopreserved P. falciparum sporozoites (PfSPZ Challenge) to evaluate safety, infectivity and PGD in Kenyan adults with low to moderate prior exposure to P. falciparum (Pan African Clinical Trial Registry: PACTR20121100033272).
RESULTS:
All participants developed blood-stage infection confirmed by quantitative polymerase chain reaction (qPCR). However one volunteer (110) remained asymptomatic and blood-film negative until day 21 post-injection of PfSPZ Challenge. This volunteer had a reduced parasite multiplication rate (PMR) (1.3) in comparison to the other 27 volunteers (median 11.1). A significant correlation was seen between PMR and screening anti-schizont Enzyme Linked Immunosorbent Assays (ELISA) OD (p = 0.044, R = -0.384) but not when volunteer 110 was excluded from the analysis (p = 0.112, R = -0.313).
CONCLUSIONS:
PfSPZ Challenge is safe and infectious in malaria-endemic populations and could be used to assess the efficacy of malaria vaccines and drugs in African populations. Whilst our findings are limited by sample size, our pilot study has demonstrated for the first time that NAI may impact on PMR post-CHMI in a detectable fashion, an important finding that should be evaluated in further CHMI studies.
AuthorsSusanne H Hodgson, Elizabeth Juma, Amina Salim, Charles Magiri, Domtila Kimani, Daniel Njenga, Alfred Muia, Andrew O Cole, Caroline Ogwang, Ken Awuondo, Brett Lowe, Marianne Munene, Peter F Billingsley, Eric R James, Anusha Gunasekera, B Kim L Sim, Patricia Njuguna, Thomas W Rampling, Adam Richman, Yonas Abebe, Gathoni Kamuyu, Michelle Muthui, Sean C Elias, Sassy Molyneux, Stephen Gerry, Alex Macharia, Thomas N Williams, Peter C Bull, Adrian V S Hill, Faith H Osier, Simon J Draper, Philip Bejon, Stephen L Hoffman, Bernhards Ogutu, Kevin Marsh
JournalFrontiers in microbiology (Front Microbiol) Vol. 5 Pg. 686 ( 2014) ISSN: 1664-302X [Print] Switzerland
PMID25566206 (Publication Type: Case Reports)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: